Recipharm makes strategic appointment in the UK & Ireland
Shabbir Mostafa to join the CDMO as Director, Business Management, with responsibility for driving sales of Recipharm’s manufacturing services.
Recipharm has invested in its UK & Ireland presence with the appointment of Shabbir Mostafa to its Business Management team.
Shabbir will join the Sweden-headquartered CDMO as Director, Business Management UK & Ireland with responsibility for supporting customers in the UK & Ireland and driving sales of Recipharm’s manufacturing services.
Commenting on the appointment, Kenth Berg, Vice President Business Management at Recipharm said: “The UK & Ireland continues to be an important market for Recipharm as we expand our localised presence throughout Europe. Our vision is to be recognised as the best-in-class provider of contract development and manufacturing solutions to the pharmaceutical industry and in order to achieve this, we are focused on attracting and recruiting excellent people.”
“As we continue to grow as a company, with our focus on decentralised operations, we are highly dependent on talented people at key posts throughout the Recipharm organisation. With his extensive knowledge of the pharmaceutical sector in the UK & Ireland, we believe Shabbir is the perfect addition to our team and will help to drive our business forward in this key market.”
With a PhD in Pharmaceutical Sciences, Shabbir joins Recipharm from Aesica Pharmaceuticals where he was the Business Development Director with responsibility for global formulation development services and the commercial finished dose business in the UK & Ireland. During his 15 year career, he has also held positions at PCI Pharma Services, Gattefossé, Patheon and IVAX Pharmaceuticals.
Shabbir said: “Recipharm is highly regarded as a significant force in the pharmaceutical sector and as the CDMO continues to expand its presence and service offering globally, it’s an exciting time to join the team. Recipharm is focused on simplifying the supply chain and managing complexity on behalf of pharmaceutical companies across the world and I look forward to playing my part by supporting our customers in the UK & Ireland.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.